21 Oct ACG 2022 Annual Scientific Meeting, Charlotte, North Carolina

Close this search box.

Business Overview

11 March, 2015

Resonance Health is a healthcare company listed on the Australian Stock Exchange (ASX:RHT). Resonance Health provides quantitative MRI based technologies for the diagnosis and monitoring of human disease. Accurate imaging end points are increasingly used in clinical trials, providing quantitative and direct evidence for regulatory submissions.

Resonance Health's image analysis laboratory provides quality certified central image analysis services to the clinical community and to clinical trials.

FerriScan® was the first product brought to market and provides an accurate non-invasive assessment of liver iron, largely removing the need for a liver biopsy in many patients with iron overload conditions.

HepaFat-Scan® gained FDA clearance in December 2013 for the measurement of fatty liver and development of an MRI based method to assess liver fibrosis continues as part of the Company's focus on developing diagnostic products to address liver disease.

Registered Office and Principal Place of Business:

141 Burswood Road
Burswood Western Australia 6100

Postal Address

PO Box 71
Burswood Western Australia 6100


96 006 762 492

Contact details:

T +61 8 9286 5300
F +61 8 9286 5399
E info@resonancehealth.com
W www.resonancehealth.com

Investor Enquiries:

Mitchell Wells

T +61 8 9286 5300
E info@resonancehealth.com


HLB Mann Judd

Level 4
130 Stirling Street
Perth Western Australia 6000

Resonance Health’s Principal Share Registry:

Advanced Share Registry Services

110 Stirling Hwy
Nedlands Western Australia 6009

T +61 8 9389 8033
F +61 8 9262 3723

Corporate Governance